New Antimicrobials for Multidrug Resistant Organisms -- Harrison Bachmeier, PharmD

แชร์
ฝัง
  • เผยแพร่เมื่อ 19 มิ.ย. 2024
  • Dr. Bachmeier presents an up-to-date review of newer-generation antimicrobials designed to be effective against infections with multiple drug-resistant pathogens. He first reviews the different types of extended-spectrum beta-lactamase (ESBL) resistance. He then discusses the significance of Carbapenemase-producing enterobacteriaceae and ESBL producing E coli, Klebsiella pneumonia, and Pseudomonas aeruginosa strains. Such organisms have become increased threats to our patients over the last two decades while new drug approvals have dwindled. Dr. Bachmeier reviews Ceftolozane-tazobactam, Ceftazidime-avibactam and their current indications. He then reviews Meropenem-vaborbactam and its utility in the treatment of Klebsiella pneumonia carbabenemase (KPC) infections. He then discusses imipenem-relebactam and its advantages in the treatment of MDR gram-negative infections. Lastly, he reviews plazomycin, eravacycline, and Cefiderocol.
    Stay in touch! Download our app on the iTunes store or find us below:
    Subscribe to our TH-cam Channel: / idpodcasts
    Visit us on our webpage: www.idpodcasts.net
    Follow us on Facebook: / id-podcasts-. .
    Tweet to us: / idpodcasts

ความคิดเห็น • 1

  • @LD-rm4ut
    @LD-rm4ut 3 ปีที่แล้ว

    Thank you for your thorough presentation. It was extremely informative!